Navigation Links
Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System
Date:8/3/2010

CLEVELAND, Aug. 3 /PRNewswire/ -- Researchers at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, a national leader in the early adoption and use of advanced treatments for cancer patients, will soon become the first in the world to test an innovative radiotherapy system from ViewRay™, Inc. The ViewRay system is designed to improve the accuracy of cancer treatments through a combination of medical imaging and radiotherapy delivery.*

Radiation therapy is critical in the fight against cancer, and nearly two-thirds of all cancer patients receive radiation therapy during their illness. However, patients and their internal organs naturally and continually move during treatment, preventing clinicians from determining precisely where the radiation is going in a patient's body. The ViewRay system is being designed to provide continuous soft-tissue MRI during treatment so that clinicians can see precisely where the radiation is being delivered, potentially improving treatment success and reducing side effects.

"This is a tremendous opportunity for us to lead the region in the implementation of real-time MRI guidance for radiation therapy for cancer patients," said Dennis Hallahan, MD, FASTRO, head of radiation oncology at the Siteman Cancer Center. "The problem of patient organ motion is one that needs to be solved. We believe the ViewRay technology holds great potential for treating patients with cancers in parts of the body that are sensitive to motion, such as the head and neck, lung, prostate and cervix. The technology fits perfectly with our mission to advance the field of cancer therapy."

"We couldn't have asked for a better partner for our technology," said ViewRay president and CEO Gregory M. Ayers, MD, PhD. "Washington University researchers are known for their groundbreaking scientific investigation and for their translation of new discoveries into meaningful clinical treatments. We are excited to be working with them to test and refine a system we believe will offer a significant advancement in radiation therapy."

* At this time, the ViewRay system is for nonclinical research use only.

About ViewRay

ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. Using MRI-guided radiotherapy, the ViewRay system is intended to provide continuous soft-tissue imaging during treatment. The system is being designed so that clinicians—for the first time—will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy, potentially improving outcomes and reducing side effects. For more information, visit http://www.viewray.com.

About the Siteman Cancer Center

The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is the only National Cancer Institute Comprehensive Cancer Center in Missouri and within a 240-mile radius of St. Louis. Siteman is also one of only 20 national members of the National Comprehensive Cancer Network, an alliance of the world's leading cancer centers dedicated to improving the quality, effectiveness and efficiency of oncology practice so patients can live better lives. For more information, visit http://www.siteman.wustl.edu .

ViewRay is a trademark of ViewRay, Inc.


'/>"/>
SOURCE ViewRay Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Inc. (Vanda) (NASDAQ: VNDA ), today announced financial ... year ended December 31, 2015. --> ... for Vanda with the continued growth of HETLIOZ in ... for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda,s President ... product portfolio builds on this success and underscores Vanda,s ...
(Date:2/10/2016)... new report from business intelligence provider GBI Research - Alzheimer,s Disease Therapeutics ... than double from just under $5 billion in 2014 to an estimated $10.4 ... Canada , France , Germany ... UK, and Japan , and will primarily be driven by ... , France , Germany , ...
(Date:2/10/2016)...  CVS Health (NYSE: CVS ) is offering ... Santa Clara County, CA , in response to ... University campus. CVS Pharmacy stores and MinuteClinic walk-in medical ... disease. Students at Santa Clara University who have not ... anyone who has had close contact with a person ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Intermedix announced on Wednesday that it ... emergency medicine professional association, to support the organization's newly established physician group with ... Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their own ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency ... to assist the local community. Pledging to select a new beneficiary every 60 ... the area. Their goal is to bring community awareness to important local causes ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited ... bottled water brand owners that topped the list as a result of their commitment ... The premier brand was Tibet 5100, a top notch water company that specializes in ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental in ... patients and families in the North Metro Denver area. The new dental practice focuses ... dentistry, and all in the most relaxing environment. , While some dental visits can ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
Breaking Medicine News(10 mins):